Survodutide Shows Significant Improvement in MASH and Liver Fibrosis in Phase 2 Trial

Patients taking the glucagon/glucagon-like peptide-1 receptor dual agonist survodutide saw an 83% improvement in ...

JULY 19, 2024

ASGE President Jennifer Christie, MD, on Highlights of Society’s DDW Presidential Plenary

ASGE President Jennifer Christie, MD, shared some highlights of ASGE’s Presidential Plenary Session to be ...

MAY 14, 2024

Treating Patients With Inflammatory Bowel Disease and Obesity

An estimated 41% of the US population is obese, including 22% of individuals aged 12 to 19 years, while nearly 1 of ...

MAY 10, 2024

Treatment Options for Pediatric Patients With MASLD

Endoscopic, surgical and pharmacologic therapies may be effective options for some children with MASLD, who are at ...

MAY 1, 2024

Advances Usher In Era of Personalized Treatment for Obesity

The multifaceted, complex medical problem that is obesity is seeing big advances that are starting to have a major ...

JANUARY 15, 2024

Patients With Cirrhosis & Diabetes May Live Longer With Metformin Plus GLP1-RA

Survival rates may improve if they take a combination of metformin and a glucagon-like peptide-1 receptor agonist.

FEBRUARY 10, 2023

Colonoscopy: Hold the Glucagon

The use of glucagon during colonoscopy reduced cecal intubation time but did not affect other parameters of ...

NOVEMBER 16, 2020